PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q4 2015 13F Holders as of 31 Dec 2015

Type / Class
Equity / COM
Total 13F shares
62,534,136
Share change
-5,084,071
Total reported value
$383,315,230
Put/Call ratio
124%
Price per share
$6.13
Number of holders
121
Value change
-$30,298,692
Number of buys
48
Number of sells
67

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q4 2015

As of 31 Dec 2015, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 121 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 62,534,136 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, Broadfin Capital, LLC, FMR LLC, BAKER BROS. ADVISORS LP, BlackRock Fund Advisors, VANGUARD GROUP INC, TUDOR INVESTMENT CORP ET AL, STATE STREET CORP, ROYCE & ASSOCIATES LLC, and MILLENNIUM MANAGEMENT LLC. This page lists 121 institutional shareholders reporting positions in this security for the Q4 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.